Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more
Shandong Lukang Pharmaceutical Co Ltd (600789) - Total Assets
Latest total assets as of September 2025: CN¥8.82 Billion CNY
Based on the latest financial reports, Shandong Lukang Pharmaceutical Co Ltd (600789) holds total assets worth CN¥8.82 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Lukang Pharmaceutical Co Ltd - Total Assets Trend (1993–2024)
This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Lukang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Lukang Pharmaceutical Co Ltd's total assets of CN¥8.82 Billion consist of 45.4% current assets and 54.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥1.79 Billion | 19.7% |
| Inventory | CN¥1.48 Billion | 16.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥893.48 Million | 9.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1993–2024)
This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Lukang Pharmaceutical Co Ltd's current assets represent 45.4% of total assets in 2024, an increase from 43.0% in 1993.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, up from 0.0% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 19.7% of total assets.
Shandong Lukang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shandong Lukang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
Eden Empire Inc
PINK:EDNEF
|
USA | $4.53 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
Shandong Lukang Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shandong Lukang Pharmaceutical Co Ltd generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shandong Lukang Pharmaceutical Co Ltd generates $ 4.34 in net profit.
Shandong Lukang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 1.20 | 0.80 |
| Quick Ratio | 0.80 | 0.83 | 0.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥623.78 Million | CN¥ 712.88 Million | CN¥ -619.13 Million |
Shandong Lukang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Lukang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | CN¥9.10 Billion |
| Market Capitalization | $828.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Lukang Pharmaceutical Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Lukang Pharmaceutical Co Ltd's assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Lukang Pharmaceutical Co Ltd (1993–2024)
The table below shows the annual total assets of Shandong Lukang Pharmaceutical Co Ltd from 1993 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.10 Billion | +3.36% |
| 2023-12-31 | CN¥8.80 Billion | +0.86% |
| 2022-12-31 | CN¥8.73 Billion | +12.04% |
| 2021-12-31 | CN¥7.79 Billion | +7.11% |
| 2020-12-31 | CN¥7.27 Billion | +2.59% |
| 2019-12-31 | CN¥7.09 Billion | +7.95% |
| 2018-12-31 | CN¥6.57 Billion | +26.25% |
| 2017-12-31 | CN¥5.20 Billion | +24.51% |
| 2016-12-31 | CN¥4.18 Billion | +3.98% |
| 2015-12-31 | CN¥4.02 Billion | -1.63% |
| 2014-12-31 | CN¥4.08 Billion | +0.25% |
| 2013-12-31 | CN¥4.07 Billion | +2.25% |
| 2012-12-31 | CN¥3.99 Billion | +14.47% |
| 2011-12-31 | CN¥3.48 Billion | +15.08% |
| 2010-12-31 | CN¥3.03 Billion | +22.06% |
| 2009-12-31 | CN¥2.48 Billion | -0.92% |
| 2008-12-31 | CN¥2.50 Billion | -0.30% |
| 2007-12-31 | CN¥2.51 Billion | +3.31% |
| 2006-12-31 | CN¥2.43 Billion | -6.06% |
| 2005-12-31 | CN¥2.59 Billion | -4.18% |
| 2004-12-31 | CN¥2.70 Billion | +0.06% |
| 2003-12-31 | CN¥2.70 Billion | +14.21% |
| 2002-12-31 | CN¥2.36 Billion | -0.79% |
| 2001-12-31 | CN¥2.38 Billion | +4.84% |
| 2000-12-31 | CN¥2.27 Billion | +26.68% |
| 1999-12-31 | CN¥1.79 Billion | +15.14% |
| 1998-12-31 | CN¥1.56 Billion | +17.20% |
| 1997-12-31 | CN¥1.33 Billion | +68.49% |
| 1996-12-31 | CN¥788.04 Million | +25.04% |
| 1995-12-31 | CN¥630.23 Million | +39.98% |
| 1994-12-31 | CN¥450.24 Million | +11.15% |
| 1993-12-31 | CN¥405.08 Million | -- |